VYNE Therapeutics (NASDAQ:VYNE) Earns “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of VYNE Therapeutics (NASDAQ:VYNE) in a research report released on Friday morning,Benzinga reports. The brokerage currently has a $5.75 target price on the stock.

VYNE Therapeutics Price Performance

NASDAQ:VYNE opened at $3.02 on Friday. The stock’s 50-day moving average is $2.19 and its two-hundred day moving average is $2.18. The stock has a market cap of $44.54 million, a PE ratio of -3.51 and a beta of 1.32. VYNE Therapeutics has a fifty-two week low of $1.57 and a fifty-two week high of $4.48.

VYNE Therapeutics (NASDAQ:VYNE) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.03). The company had revenue of $0.20 million during the quarter, compared to analyst estimates of $0.11 million. VYNE Therapeutics had a negative net margin of 6,896.55% and a negative return on equity of 41.23%. On average, equities research analysts anticipate that VYNE Therapeutics will post -0.86 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in VYNE Therapeutics stock. Lynx1 Capital Management LP purchased a new stake in shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 16,194 shares of the company’s stock, valued at approximately $32,000. VYNE Therapeutics comprises approximately 0.0% of Lynx1 Capital Management LP’s holdings, making the stock its 17th biggest position. Lynx1 Capital Management LP owned approximately 0.11% of VYNE Therapeutics as of its most recent filing with the Securities and Exchange Commission. 83.78% of the stock is owned by institutional investors.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.